Alphabet’s Verily, formerly Google Life Sciences, and Johnson & Johnson join forces in the creation of Verb Surgical for robot-assisted surgery which aims to “develop novel technologies and solutions to help improve the standard of care around the world.” According to Gary Pruden, Worldwide Chairman, Johnson & Johnson Medical Devices, their team had made a “meaningful progress on the robotics platform.”
Quoted from the press release:
In the coming years, Verb Surgical aims to develop a comprehensive surgical solutions platform that will incorporate leading-edge robotic capabilities and best-in-class medical device technology for operating room professionals. The goal of Verb Surgical is to develop these new technologies in partnership with surgeons and hospitals to enable better patient outcomes, improve access to minimally invasive surgery, and achieve greater hospital efficiency.
A study suggests that women with polycystic ovarian syndrome (PCOS), an endocrine disorder affecting women of reproductive age and said to affect 5 to 10 percent of that population, have a high risk of giving birth to babies with autism spectrum disorder (ASD).
Quoted from article:
The Karolinska Institute’s Renee Gardner, along with colleagues from Sweden and the U.S., tapped into a Swedish national population health database to look at potential ties between PCOS and ASD. As they reported online December 8 in Molecular Psychiatry, the team looked at 23,748 individuals with ASD and nearly 209,000 unaffected individuals, all born in Sweden between 1984 and 2007.
Mexico’s regulators were the first to approve Dengvaxia and endorsed the vaccine to people between the ages of 9 and 45 residing in areas where dengue outbreak is prevalent. According to Charmeil, Sanofi is trying to make “dengue a preventable disease.” According to a sales analysis from Bloomberg, “Dengvaxia’s sales may reach $1.4 billion by 2020”.
Quoted from article:
Sanofi expects more approvals in “upcoming weeks” for the product, called Dengvaxia, in Latin America and Asia, Olivier Charmeil, who heads the Paris-based company’s vaccines unit, said in a telephone interview. The injection can thwart all four types of the virus, which has appeared in Portugal, France, Florida and Japan recently and increased the risk of “explosive outbreaks,” according to the World Health Organization.